The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A pilot study of dose-dense (biweekly) carboplatin plus paclitaxel with or without trastuzumab as neoadjuvant treatment for breast cancer.
Teng Zhu
No relevant relationships to disclose
Guochun Zhang
No relevant relationships to disclose
XueRui Li
No relevant relationships to disclose
YanHui Liu
No relevant relationships to disclose
Fangping Xu
No relevant relationships to disclose
Jian Zu
No relevant relationships to disclose
Ning Liao
No relevant relationships to disclose
Kun Wang
No relevant relationships to disclose